New Medications May Offer Hope to Drinkers Battling Alcohol Dependence

Individuals who experience the physical, mental and social symptoms associated with alcohol dependence are offered hope through the results of two recent studies by researchers at the Medical University of South Carolina (MUSC). In separate investigations, researchers found favorable results for a medication to help heavy drinkers who are trying to modify their consumption, as well as a medication to reduce alcohol withdrawal symptoms and prevent relapse.

In a landmark study, MUSC researchers working with investigators at the University of Virginia Health System and elsewhere have found that topiramate, an effective therapeutic medication, not only decreases heavy drinking, but it also lowers all liver enzymes, plasma cholesterol, body mass index (BMI), and systolic and diastolic blood pressure — all of which tend to increase with heavy drinking and pose such serious health risks as heart disease and cirrhosis. Notably, these combined effects suggest that topiramate may decrease the risk of heart disease in alcohol dependent individuals.

“These findings add growing data indicating that heavy drinkers who modify their drinking with the help of medication and supportive counseling may see an improvement in health and well-being, as well as a potential reduction of risk for the development of heart and liver diseases. This shows that treatment of alcoholism has potential health benefits beyond the immediate behavioral and emotional improvement caused by a reduction in drinking” said Raymond Anton, M.D., distinguished university professor.

By decreasing liver enzymes and cholesterol levels, topiramate also may reduce the risk of fatty liver disease, which leads to cirrhosis – a common consequence to end-stage liver disease leading to death in some alcoholics.

Additionally, topiramate significantly contributed to a decline in obsessive thoughts and compulsions, components of alcohol craving, and also had a greater improvement in their “overall quality of life,” and specifically an improvement in general and leisure activities and household duties, as well as a reduction in sleep disturbances.

The Food and Drug Administration has approved topiramate for seizures and migraine headaches, but it is not currently approved for treating alcohol dependence. Ortho-McNeil Neurologics, Inc., manufactures topiramate and provided study funding.

Results from the nationwide 14-week trial involving 371 male and female diagnosed alcoholics was published in the June 9 issue of the Archives of Internal Medicine.

In addition, Anton presented initial results from a separate investigation of a 14-week double-blind, placebo-controlled study utilizing the PROMETA ® alcoholism treatment program, developed by Hythiam, inc., at the 2008 Research Society on Alcoholism (RSA) conference in Washington D.C.

Anton suggested that alcohol dependence programs are few in number and not exceptionally effective, which is particularly true for individuals who experience alcohol withdrawal symptoms. PROMETA ®, a combination of generic medications, reduced cravings and alcohol withdrawal symptoms, promoted abstinence, and improved mood and sleep only in those who had symptoms of alcohol withdrawal. Although the PROMETA ® Protocol has been marketed nationally, this was the first scientific study examining its utility in individuals with alcohol dependence.

At the time of the RSA presentation, the data presented covered the initial six-week active treatment phase of the 14-week study. While these are initial findings, additional evaluation of the full 14-week study data is ongoing, and Anton plans to release these specifics in a peer-reviewed publication.

MUSC has an ongoing clinical trial program studying new medications for the treatment of alcohol use disorders. For more information call 843-792-2727.
__________
source: Newswise Medical News

More Treatment & Detox Articles

A nudge towards sobriety and health?

If you picked up a bottle of wine and read on the label “The average British drinker drinks one glass of wine a night”, would it make you think twice before refilling your glass? The Conservatives believe it might – and that public information along those lines is one possible way to reduce binge drinking…..

Binge drinking – the Maltese way

Maltese boozers start younger but handle their drink better, an international study finds. And while the law has often been amended to address issues such as underage drinking, enforcement has to date been scant. James Debono analyses our alcohol culture through statistics Maltese teenagers are more likely to binge than their peers in the United….

Alcohol rehab numbers outstrip hard drugs

Alcohol has again outstripped illicit drugs like heroin and ice as the number one reason for admissions at a major Australian rehab service. Problem drinking topped Odyssey House’s 2009 admission list, because 26 per cent of those seeking care over the year named it as their “principal drug of concern”. It was fractionally down from….

How can dual diagnosis be treated

A person with Dual diagnosis is affected with substance abuse and mental health disorder at the same time. Therefore, it is very important to find out the cause of substance abuse and mental health problem, individually in these people and to study and then draft out a proper method for the diagnosis of this dual….

Drug testing

Drug testing basically involves collecting the urine samples to test the different drugs like cocaine, marijuana, PCP, amphetamines, etc. The teenagers, are especially more vulnerable to drug abuse as their body and brains are still developing. This can lead to adverse effects on his health, body, behavior and brain. There are number of methods that….